

POSTER PRESENTATION

Open Access

A multi-center study of high dose Aldesleukin (Proleukin®)(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF^{V600} mutation positive metastatic melanoma (proclivity 01)

Joseph Clark¹, Lawrence Flaherty², Marc Ernstoff³, Henry Koon⁴, Mohammed Milhem⁵, Gerald Militello⁶, Sanjiv Agarwala⁷, Brendan Curti⁸, Lee Cranmer⁹, Christopher D Lao¹⁰, Theodore F Logan¹¹, Jose Lutzky¹², Venkatesh Rudrapatna¹³, Gregory Daniels¹⁴, Bret Taback¹⁵, Sandra Aung¹⁶, James Lowder^{16*}, David Lawson¹⁷

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Purpose

To investigate whether the Vemurafenib-induced increased tumor antigen expression, T lymphocyte infiltration and tumor debulking improve the complete response rate induced by HD IL-2 in metastatic melanoma and if there is synergistic toxicity using the drugs in close approximation.

Schema

Adult patients with measurable metastatic or unresectable Stage III melanoma with no prior therapy and a BRAF^{V600} mutation who are candidates for HD IL-2 are eligible for entry into the first cohort of 135 patients (figure 1). Six weeks of Vemurafenib therapy per package insert precedes




Figure 1 Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib.

¹⁶Prometheus Laboratories, San Diego, CA, USA
Full list of author information is available at the end of the article

up to 2 courses of HD IL-2. Vemurafenib is administered during the outpatient intervals between cycles of HD IL-2 and following completion. A second cohort of up to 50 similar patients already responding or stable with < 18 weeks of Vemurafenib therapy will also be accrued. The study was amended to permit prior anti-PD-1 therapy. The primary endpoint is Complete Response (CR) and near CR at 6 months of therapy.

Current status

Sixteen sites have enrolled patients. 41 patients have been enrolled to date, 27 in Cohort 1 and 14 in cohort 2. The Data Safety and Monitoring Board performed an initial safety analysis after the initial 8 patients which demonstrated no unexpected safety signal. An analysis of the effect of the combination on Progression Free Survival in both cohorts will be performed after the first 20% of patients in Cohort 1 have received at least one course of HD IL-2. The results of this analysis should be available at the time of the SITC meeting.

Authors' details

¹Loyola University, Maywood, IL, USA. ²Karmanos Cancer Center, Detroit, MI, USA. ³Dartmouth University, Hanover, NH, USA. ⁴CWRU University Hospitals, Cleveland, OH, USA. ⁵University of Iowa, Iowa City, IA, USA. ⁶Hematology/Oncology Clinic, USA. ⁷Saint Luke's Cancer Center, Center Valley, PA, USA. ⁸Earle A. Chiles Research Institute, Portland, OR, USA. ⁹University of Arizona Cancer Center, Tucson, AZ, USA. ¹⁰University of Michigan, Ann Arbor, MI, USA. ¹¹Indiana University, Indianapolis, IN, USA. ¹²University of Miami Medical Center, Miami, FL, USA. ¹³University of Minnesota, Minneapolis, MN, USA. ¹⁴Moore's Cancer Center, La Jolla, CA, USA. ¹⁵Columbia University, New York, NY, USA. ¹⁶Prometheus Laboratories, San Diego, CA, USA. ¹⁷Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P77

Cite this article as: Clark *et al.*: A multi-center study of high dose Aldesleukin (Proleukin®)(HD IL-2) + Vemurafenib (Zelboraf®) therapy in patients with BRAF^{V600} mutation positive metastatic melanoma (proclivity 01). *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P77.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

